Actively Recruiting

Phase 4
Age: 18Years +
All Genders
NCT03153527

Taper Or Abrupt Steroid Stop: TOASSTtrial

Led by University Hospital, Basel, Switzerland · Updated on 2026-04-22

530

Participants Needed

16

Research Sites

521 weeks

Total Duration

On this page

Sponsors

U

University Hospital, Basel, Switzerland

Lead Sponsor

K

Kantonsspital Baselland Bruderholz

Collaborating Sponsor

AI-Summary

What this Trial Is About

This study is an Investigator-initiated, placebo-controlled, multicenter noninferiority trial, comparing rapid termination of systemic glucocorticoid treatment with a tapering regime over 4 weeks.

CONDITIONS

Official Title

Taper Or Abrupt Steroid Stop: TOASSTtrial

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Signed informed consent
  • Age 18 years or older
  • Taking daily glucocorticoid dose of 7.5 mg prednisone-equivalent or higher at inclusion
  • Glucocorticoid therapy for at least 28 days with an average daily dose of 7.5 mg or more and cumulative dose of at least 420 mg prednisone-equivalent before inclusion
  • No longer needing tapering to treat the underlying disease
Not Eligible

You will not qualify if you...

  • Primary adrenal failure
  • Treatment with systemic depot glucocorticoids (e.g., intramuscular, epidural)
  • Unable to take glucocorticoid cover treatment during stress
  • Unable or unwilling to provide informed consent
  • Pregnant or breastfeeding women
  • Planning to become pregnant during the study
  • Lack of reliable contraception for women of childbearing potential
  • Known or suspected non-compliance
  • Unable to follow study procedures due to language, psychological, or cognitive issues
  • Participation in another investigational drug study within 30 days before or during this study
  • Previous enrollment in this study
  • Investigator, family members, employees, or dependents enrolled

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 16 locations

1

University Hospital Frankfurt

Frankfurt, Germany

Actively Recruiting

2

University Hospital Würzburg

Würzburg, Germany, 97080

Actively Recruiting

3

Departement of Internal Medicine, Kantonsspital Aarau

Aarau, Switzerland, 5001

Actively Recruiting

4

Kantonsspital Baden

Baden, Switzerland, 5404

Actively Recruiting

5

Endocrinology/Diabetology/Metabolism; University Hospital Basel

Basel, Switzerland, 4031

Terminated

6

St. Claraspital Basel

Basel, Switzerland, 4058

Actively Recruiting

7

Department of Rheumatology, Immunology, and Allergology, Inselspital

Bern, Switzerland, 3010

Terminated

8

Division of Gastroenterology, Spital Bülach AG

Bülach, Switzerland, 8180

Terminated

9

Kantonsspital Frauenfeld

Frauenfeld, Switzerland, 8501

Actively Recruiting

10

Geneva University Hospitals

Geneva, Switzerland, 1205

Actively Recruiting

11

Center for Primary Health Care,University of Basel, Kantonsspital Baselland

Liestal, Switzerland, 4410

Terminated

12

Internal Medicine, Kantonsspital Baselland/Liestal

Liestal, Switzerland, 4410

Actively Recruiting

13

Department of Internal Medicine, Kantonsspital Münsterlingen

Münsterlingen, Switzerland, 8596

Actively Recruiting

14

Stoffwechselzentrum, Kantonsspital Olten

Olten, Switzerland, 4600

Terminated

15

Department of Internal Medicine, Kantonsspital St. Gallen

Sankt Gallen, Switzerland, 9007

Actively Recruiting

16

Dept. of Endocrinology, Diabetology and Clinical Nutrition, University Hospital

Zurich, Switzerland, 8091

Terminated

Loading map...

Research Team

J

Jonas Rutishauser, Prof MD

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

QUADRUPLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here